Human TNFSF4 ELISA Kit, Lot 21AO-592 [Cancer Immune Checkpoint Assay Kit]
CAT#: IOK-05-P503
Product Type: ELISA Kit
Target: TNFSF4
Short Description
The kit is designed for in vitro quantitative measurement of Human TNFSF4 in Cell Culture Supernatant, Plasma (EDTA - heparin), Serum.
Description
Sandwich ELISA for Quantitative Detection of Antigen
Applications
ELISA
Application Notes
Useful in Sandwich ELISA for Quantitative Detection of Antigen. Aliquot 0.1 mL per well of the 10000pg/mL, 5000pg/mL, 2500pg/mL, 1250pg/mL, 625pg/mL, 313pg/mL, 156pg/mL human TNFSF4 standard solutions into the precoated 96-well plate. Add 0.1 mL of the sample diluent buffer into the control well (Zero well). Add 0.1 mL of each properly diluted sample of human cell culture supernates, serum or plasma (heparin, EDTA) to each empty well. Blood Product Anticoagulant: Heparin Sodium. ELISA Dilution: 156pg/mL-10000pg/mL.
Production: Natural and recombinant human TNFSF4. There is no detectable cross-reactivity with other relevant proteins. Standard: Expression system for standard: NSO, Immunogen sequence: Q51-L183
Sample Volume
100 μL
Plate
Pre-coated
Storage
RT,4 °C,-20 °C
Storage Comment
Store vials at 4°C prior to opening. Centrifuge product if not completely clear after standing at room temperature. This product is stable for 6 months at 4°C as an undiluted liquid. Dilute only prior to immediate use. For extended storage freeze at -20°C or below for 12 months. Avoid cycles of freezing and thawing.
Note
Store vials at 4°C prior to opening. Centrifuge product if not completely clear after standing at room temperature. This product is stable for 6 months at 4°C as an undiluted liquid. Dilute only prior to immediate use. For extended storage freeze at -20°C or below for 12 months. Avoid cycles of freezing and thawing.
Restrictions
For Research Use only
Alternative Name
Tumor Necrosis Factor Ligand Superfamily, Member 4 (TNFSF4)
Cellular Response to Molecule of Bacterial Origin, Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Production of Molecular Mediator of Immune Response, Activated T Cell Proliferation, Cancer Immune Checkpoints